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In this study the long-term prognosis was analysed of all 462 consecutive f male breast cancer patients who were diagnosed 
and carefully staged between 1970 and 1980 in a 600-bed community hospital in Eindhoven, south east Netherlands. 
Follow-up of recurrence and causes of death was obtained until ! January 1993. Observed survival rates at 5, 10 and 20 
years were 66%, 45% and 32%, respectively, and the corresponding breast cancer-specific survival rates were 71%, 54% 
and 44%. The yearly risk for a recurrence of breast cancer after treatment s eadily decreased from 10% the first year to 
1% after 10 years. 
In a multivariate survival analysis both tumour size and nodal status appeared to be equally important prognostic factors 
in the first 5 years after diagnosis. After 5 years only tumour size had independent prognostic value, which was not 
significant any more after 10 years. In patients with a tumour size ~< 2 cm and without lymph node involvement a diagnosis, 
the risk for a recurrence was found to be negligible after 10 years. Those patients may be considered cured, although a 
search for early diagnosis of a second primary breast cancer in this group is still advisable. 
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Introduction 
Although the percentage of long-term survivors after breast 
cancer is relatively high, a cure is unlikely to be confirmed 
before at least 15 years follow-up) -6 Because decisions 
on continuation of routine control visits should be well 
founded, more detailed knowledge regarding the time 
periods during which prognostic factors have their greatest 
influence may be of practical value. 7This may also add to 
the knowledge on the related biological mechanisms. 
However, in breast cancer, contrary to factors which pre- 
dict short-term survival, little is known about the factors 
predicting long-term survival. ~" 8-~0 
This report presents survival rates of carefully staged and 
documented breast cancer patients diagnosed between 1970 
and 1980 in a general hospital in south east Netherlands, 
with follow-up until 1993. The prognostic potential of 
tumour size, nodal status and age group is investigated 
within different follow-up intervals. 
Material and methods 
The study includes all patients with breast cancer diagnosed 
between 1970 and 1980 in the Sint Joseph Hospital in 
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Eindhoven (now Veldhoven), a community hospital of about 
600 beds. Clinical staging was done according to the UICC 
classification, 1968) t Tumour size was measured by the 
pathologist and divided into three categories: pTl (~< 2 cm), 
pT2 (2-5 cm), or pT3 (> 5 cm). Axillary lymph node status 
was divided into three categories: pN0 (lymph node nega- 
tive), pNl (lymph node positive, without involvement of the 
apex and without extra nodal growth), or pN2 (lymph node 
positive with involvement of the apex of the axilla, or with 
extra nodal growth). Up to 1974 pre-operative biopsy of the 
apex lymph nodes was usual, followed by a complete axillary 
clearance when lymph nodes were negative on frozen section. 
After 1974 an immediate complete axillary dissection en bloc 
with a mastectomy was common practice. The presence of 
distant metastasis was screened by clinical and laboratory 
investigations, routine chest radiographs, and by more 
advanced techniques, if indicated. Overall, four surgeons 
were involved in the treatment of breast cancer patients, 
who mainly tlsed radical (before mid-1976) and modified 
radical (after mid-1976) mastectomy. Patients with central 
or medial tumour localization received adjuvant radio- 
therapy to the parasternal lymph nodes. Patients with pT3 
tumours and/or three or more axillary lymph nodes received 
radiotherapy to the supraclavicular, axillary, parasternal 
lymph nodes and the chest wall. In 1979 adjuvant CMF 
treatment was introduced for premenopausal axillary lymph 
node positive patients, and only 18 patients received this 
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therapy. After primary treatment patients were seen in the 
out-patient clinic every 3 months in the first 2 years, every 
6 months up to 5 years, and annually thereafter, z-" In this 
period of diagnosis in Eindhoven there were two other 
general hospitals. To our knowledge there was no particular 
case selection or referral to other institutions for a sub- 
stantial number of patients. 
Active follow-up was carried out up to 1 January 1993. 
Causes of death could be traced. Death from breast cancer 
included only those patients with known metastases. Only 
12 patients (3%) were lost to follow-up after variable inter- 
vals of observation. 
Observed (actuarial) survival curves were computed, t3 
according to age category (under 50, 50-65, 65+ years), 
tumour size and nodal status. Breast cancer-specific survival 
was calculated by considering patients withdrawn from the 
study at the moment of non-breast cancer death. Disease- 
free survival was calculated for patients without distant dis- 
ease at diagnosis to recurrence, the end of the study, or to 
death. Differences in survival were assessed by the log-rank 
test, also after adjustment by stratification for other vari- 
ables. The Cox proportional hazards model was used to 
simultaneously evaluate the prognostic importance of age, 
tumour size and nodal statusJ 4This was done separately for 
the first and second 5-year follow-up interval, and for the 
subsequent 10-year interval. Other statistical methods are 
indicated in the text. P-values given are two-sided; five per- 
cent was considered the limit of significance. 
Results 
The number of patients according to clinical stage, patho- 
logical tumour size and lymph node status is listed in Table 
I. Overall, 462 patients were included with a mean age at 
diagnosis of 57 years (range, 23 to 90 years). Age category 
did not correlate with pathological tumour size or lymph 
node status (Kruskal-Wallis tests, P-values > 0.1). During 
the first 5 years of follow-up, 158 women were reported 
dead: 132 (84%) due to breast cancer. After 10 years another 
99 women had died, 70 (71%) due to breast cancer; and after 
Table 1. Characteristics of the patient group 
Number of patients % 
Clinical stage 
I 103 22 
I I 204 44 
Ill 115 25 
IV 34 7 
Unknown 6 1 
Tumour size 
pT 1 134 29 
pT2 246 53 
pT3 60 13 
Unknown 22 5 
Lymph nodes 
pN0 231 50 
pNI 101 22 
pN2 101 22 
Unknown 29 6 
Total 462 100 
20 years another 37 women had died, 24 (65%) due to breast 
cancer. 
Observed survival rates for the total group at 5, 10, and 
20 years were 66°/0, 45%, and 32%, respectively; the cor- 
responding breast cancer-specific survival rates were 71%, 
54% and 44%. In patients without distant metastasis at 
diagnosis the risk for a recurrence steadily decreased from 
an annual 10% in the first two years after treatment to 
about 1% after 10 years; thereafter, this decrease continued. 
Clinical stage predicted breast cancer survival very well 
(P < 0.001, Fig. 1). 
Within the node negative patient group (pN0), prognosis 
in pTI patients was significantly better than in pT2 and 
pT3 patients (P < 0.01), but prognosis was not significantly 
different between pT2 and pT3 patients (P > 0.2; Fig.. 2). 
Among the node-positive patients, pTl patients had a more 
favourable prognosis than pT2 and pT3 patients (P < 0.01), 
and pT2 than pT3 patients (P < 0.01, Fig. 3). After 10 years 
of follow-up, 72% of the pTIN0 patients (n = 79), were free 
of recurrence; of these women, only one patient developed 
a recurrence afterwards. In fact, of the 79 pTIN0 patients 
surviving for 10 years, there was only one recurrence in the 
remaining 488 cumulative follow-up years. 
In the first 5 years of follow-up both tumour size and 
lymph node status were significant prognostic factors for 
disease-free survival, with approximately equal lbower in a 
Cox regression analysis (Table 2). The second 5 years of 
follow-up, tumour size was again an important prognostic 
factor, in contrast to nodal status. After 10 years of follow- 
up the prognostic effect of tumour size remained, although to 
a smaller extent. The independent effect of age on prognosis, 
adjusted for tumour size and nodal status, was very small: 
only the oldest age group had a better prognosis in the first 
5 years of follow-up and a worse prognosis after 10 years of 
follow-up as compared to the reference category; however, 
both these estimates were only borderline significant. 
Discuss ion 
The present analysis hows that the prognostic influence of 
tumour size remains present for a longer time period as 
compared to nodal status. This finding is in line with the 
results reported by Toikkanen et alJ ° Their study among 
10-year survivors of breast cancer, showed that tumour size 
remained a significant prognostic factor after l0 years of 
follow-up, whereas nodal status only predicted survival for 
the first l0 years of follow-up. The finding that the prog- 
nostic effect of nodal status has disappeared after 5 years is 
in agreement with the results reported by Lipponen et al. s 
They found that the marked prognostic influence of both 
tumour size and nodal status diminished steadily during the 
first 5 years of follow-up, becoming non-significant after 
5 years of follow-up. 
In this analysis of breast cancer survival the influence of 
prognostic factors considerably changed over time. There- 
fore, it is advised to distinguish between short follow-up 
intervals in survival analyses. 
An earlier analysis of this patient group showed that the 
great majority of local recurrences were detected uring 
routine control visits, ~2 and that the intensive search for 
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Fig. 1. Breast cancer-specific survival according to clinical stage at diagnosis. 
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Table 2. Rate ratios (95% CI) for disease recurrence per follow-up interval, according to age, 
postoperative tumour size and nodal status 
Follow-up interval 
Factor 0-5 years 5-10 years 10-20 years 
Age group (years) 
< 50* I 1 1 
50-65 0.St (0.5-1. l) 0.St (0.3-1.8) 1.0 (0.1-17) 
65-1- 0.7t (0.5-1.0) 1.5? (0.7-3.5) 10 (1.0-104) 
Tumour size 
pTl* I 1 I 
pT2 2.0 (1.3-3.1) 6.4t (2.2-19) 4.3~ (0.4-41) 
pT3 3.4 (1.9-5.8) 5.7§ (I.2-26) 
Nodal status 
pN0* I 1 I 
pN 1 1.9 (1.3-2.7) 0.9? (0.4-2. I) 0.5§ (0. I-5) 
pN2 3.5 (2.4-5.2) 1.2t (0.4-3.2) 
* Reference category. 
t Estimates are not significantly different from each other. 
:~ Estimate for pT2 and pT3 combined vs pT1. 
§ Estimate for pN + vs pN0. 
distant disease by routine follow-up means did not appear 
to be beneficial to the patients. From this study it was con- 
cluded that follow-up after treatment of primary breast 
cancer should be limited to taking the history, physical 
examination with emphasis on the Ioco-regional status, and 
an annual mammography for the detection of contralateral 
breast cancer. In the present analysis it appeared that the 
risk for a recurrence steadily decreased uring follow-up, 
and that after I0 years of follow-up it became very small, 
particularly in patients with pTIN0 tumours. Weighing the 
advantage of a very small chance for detecting a recurrence 
against he disadvantage of many follow-up visits and exam- 
inations, we conclude that pT IN0 breast cancer patients 
who survive for 10 years may be considered cured, with no 
need for further outine follow-up visits for the detection of 
metastasis. However, the increased risk of a contralateral 
breast cancer, 15" 16 may well warrant a search for early diag- 
nosis of a second primary breast cancer.17 
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